George D. Yancopoulos

Stories

Olatorepatide Phase III data show 19.3% weight loss with low nausea rates

As of October 2026: Leading Regeneron's olatorepatide registrational program

Hansoh Pharma presented full Phase III results for olatorepatide at the European Association for the Study of Diabetes meeting in Milan on October 2. Overweight and obese patients on the highest 15 mg dose lost 19.3% of their body weight on average by week 48, and the weight-loss curve had not flattened.

Updated Oct 2

Dupixent becomes one of the most versatile drugs in pharmaceutical history

New Capabilities

As of May 2026: Leading Regeneron's scientific strategy and Dupixent expansion

Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.

Updated May 29

Notable Quotes

We are encouraged by the olatorepatide Phase 3 results in this Chinese population, which demonstrate not only meaningful weight loss but also a tolerability profile that could make a real difference in patients' day-to-day experience on treatment.

from Olatorepatide Phase III data show 19.3% weight loss with low nausea rates · Updated Oct 2

"With this approval, Dupixent once again demonstrates its value in advancing the treatment landscape for a chronic type 2 inflammatory disease with high unmet need. Beyond reducing nasal signs and symptoms, Dupixent reduced the need for surgery or systemic corticosteroids with fewer patients having bone erosion in the sinuses." — on AFRS approval, February 2026

from Dupixent becomes one of the most versatile drugs in pharmaceutical history · Updated May 29

"We have programs that are first in class, the first drug that can really make a difference. Dupixent is a great example of such a drug that has changed an entire landscape for all these allergic diseases." — to shareholders, 2020

from Dupixent becomes one of the most versatile drugs in pharmaceutical history · Updated May 29